Brooke Berry was Analytical Study Director at Q-Pharm Pty Ltd for the acquisition, analysis, and interpretation of pharmacokinetic data. Manuscript preparation and review was undertaken personally, with some financial assistance from sponsor, Advanced Medical Institute Pty Ltd.
Comparison of Pharmacokinetics of Vardenafil Administered Using an Ultrasonic Nebulizer for Inhalation vs. a Single 10-mg Oral Tablet
Article first published online: 28 JUL 2009
© 2009 International Society for Sexual Medicine
The Journal of Sexual Medicine
How to Cite
Berry, B., Altman, P., Rowe, J. and Vaisman, J. (2009), Comparison of Pharmacokinetics of Vardenafil Administered Using an Ultrasonic Nebulizer for Inhalation vs. a Single 10-mg Oral Tablet. Journal of Sexual Medicine. doi: 10.1111/j.1743-6109.2009.01403.x
- Issue published online: 28 JUL 2009
- Article first published online: 28 JUL 2009
- PDE5 Inhibitor
Introduction. Delivery of vardenafil (for improvement of erectile function) via the inhaled route of administration may be advantageous in that this avoids extensive first pass metabolism and may therefore increase the bioavailability (hence the reliability of absorption) and shorten the time of pharmacological onset of activity. A unique nebulizer design has been developed by the sponsor (Advanced Medical Institute Pty Ltd) that is capable of delivering relatively large volumes of drug.
Aim. The primary objective of the Phase 1 study was to assess and compare the pharmacokinetics of a single dose of vardenafil 10-mg tablet and a single dose of vardenafil solution administered via inhalation using an ultrasonic nebulizer device. Secondary objective was to assess the safety of vardenafil administered via inhalation using an ultrasonic nebuliser device.
Methods. Two-part study in healthy volunteers. Dose-ranging study was performed in two subjects to determine the appropriate inhalational dose, followed by an open, randomized, crossover, single dose pharmacokinetic study in 12 subjects, which compared a single 10-mg oral dose to the inhalation dose.
Main Outcome Measures. Cmax, Cmax/Dose, Tmax, ke, t1/2, AUC0–t, AUCt–∞, AUC0–∞, AUC0–∞/Dose, and % area extrapolated.
Results. The two treatments are not bioequivalent, with vardenafil absorbed and eliminated faster and with less variability using the nebulizer for drug delivery. Administration via the inhalational route was not associated with any clinically significant changes in blood pressure or heart rate, and no serious adverse events were recorded, demonstrating an acceptable safety profile.
Conclusion. To our knowledge, this is the first report of the administration of vardenafil HCl via the pulmonary route of administration. This trial demonstrates that vardenafil HCl may be administered using the ultrasonic nebulizer to reach blood levels comparable with those produced by a vardenafil 10-mg oral tablet, faster and using less drug. This new route of administration may potentially improve the onset of action, reliability, and safety for this class of drug. Berry B, Altman P, Rowe J, and Vaisman J. Comparison of pharmacokinetics of vardenafil administered using an ultrasonic nebulizer for inhalation vs. a single 10-mg oral tablet. J Sex Med **;**:**–**.